Bank of Valletta has announced that its Żurrieq Branch will be temporarily closed until further notice from Wednesday 21 October, as a staff member has tested positive for COVID-19.
In the meantime, the bank has announced that its Gżira and Marsa branches will reopen on Wednesday, 21 October. The bank hired an infection management control company to disinfect the branches and the branches are now safe to reopen for business after approval by the health authorities.
#MaltaDaily
The government has said it would initially spend £33.6 million on the studies, but regulators and the ethics committees will need to approve the study before they can move forward.
If approved, a potential vaccine which has proven to be safe in initial trials will be offered to healthy volunteers between the ages of 18 and 30. In a controlled environment, they will then be exposed to COVID-19 and monitored 24 hours a day to see if the vaccine works and whether there are any side effects.
Study advocates believe the approach will produce results quicker than conventional studies, as volunteers are not waiting to be exposed to the disease-which could potentially save thousands of lives.
#MaltaDaily
In his latest parliamentary conference, Deputy Prime Minister Chris Fearne stated that Malta has ordered sufficient COVID-19 vaccines to cover the country’s entire population within six months.
Fearne also reiterated the fact that 100,000 people were vaccinated for influenza after a week in operation.
The COVID-19 vaccines will come from pharmaceutical companies AstraZeneca, Johnson & Johnson and Astra Zeneca as part of a deal signed off by the European Commission.
In his latest parliamentary conference, Deputy Prime Minister Chris Fearne stated that Malta has ordered sufficient COVID-19 vaccines to cover the country’s entire population within six months.
Fearne also reiterated the fact that 100,000 people were vaccinated for influenza after a week in operation.
The COVID-19 vaccines will come from pharmaceutical companies AstraZeneca, Johnson & Johnson and Astra Zeneca as part of a deal signed off by the European Commission.
